Novartis India profitability ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023

Returns
	13.2%	11.2%	13.3%
	10.8%	8.9%	10.5%
	11.3%	7.9%	7.2%
	9.4%	6.2%	—
Margins
	25.7%	19.5%	17.2%
	25.1%	18.7%	15.6%
	125.4%	−8.3%	—
	36.6%	36.7%	30.5%
	28.3%	25.4%	27.3%
Additional
	22.6%	30.7%	10.4%
	13.2%	11.2%	13.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

NOVARTIND₹1,790.00

Novartis India Limited

· Pharma & Health

₹ CrorePeersBPLPHARMA JENBURPH KPL MAKERSL PARNAXLAB SGRL SHUKRAPHAR SUNLOC

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025
Returns
Return on Common Equity	13.33	11.21	13.19
Return on Assets	10.52	8.93	10.78
Return on Capital Employed	7.17	7.87	11.34
Return on Invested Capital	—	6.20	9.42
Margins
EBITDA Margin	17.18	19.48	25.66
Operating Margin	15.58	18.70	25.05
Incremental Operating Margin	—	-8.31	125.38
Pretax Margin	30.46	36.66	36.61
Net Income Margin	27.29	25.42	28.32
Additional
Effective Tax Rate	10.42	30.65	22.63
Sustainable Growth Rate	13.33	11.21	13.19

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.